Epileptic seizures nearly vanish after people receive experimental gene therapy in their brains

Epilepsy patients could soon live with far fewer seizures, easing daily disability, reducing dependence on medication, and lessening the emotional strain on families. A therapy that cuts seizure burden by roughly nine‑tenths promises a shift in clinical outcomes and a new market for biotech firms invested in neuromodulation. Hospitals could see fewer emergency visits, and insurers may face lower payout demands, while patients anticipate returning to work or school with fewer interruptions.

The reduction stems from an experimental chemogenetic approach that installs designer receptors—known as DREADDs—into patient brain cells, allowing externally administered compounds to silence hyperactive networks. Researchers in China have begun human trials of this gene‑editing strategy, marking the first clinical use of a tool long confined to laboratory studies. South China Morning Post reported a 92.6% seizure drop, while The Independent cited a 90% decline and Nature described seizures as nearly vanishing after treatment.

CGTN highlighted the early success of the DREADDs test, and Chemical & Engineering News noted the transition of the designer‑receptor method from lab to patients. The next step will be larger safety studies and regulatory review to determine if the initial promise can be replicated.